Navigation Links
Global Atrial Fibrillation Market is Expected to Reach USD 14.8 Billion in 2019: Transparency Market Research
Date:11/1/2013

Albany, New York, USA (PRWEB) November 01, 2013

According to a new market report published by Transparency Market Research "Atrial Fibrillation Market (Pharmacological and Non-Pharmacological Treatment, Electric Cardioversion, Radiofrequency, Cryo, Laser and Microwave Catheter Ablation, Maze Surgery, Anti-Coagulant and Anti-Arrhythmic Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global market for atrial fibrillation was valued at USD 6.1 billion in 2012 and it is expected to reach an estimated value of USD 14.8 billion in 2019, growing at a CAGR of 13.4 percent from 2013 to 2019.

Browse the full report with complete TOC at http://www.transparencymarketresearch.com/atrial-fibrillation-market.html.

Rising global base of geriatric population inducing an accelerated growth in the incidence rates of atrial fibrillation is one of the highest impact-rendering drivers for this market. In addition, favorable results exhibited by clinical trials promoting combined pharmacological therapy such as the HARMONY trial and rising prevalence of disorders causing atrial fibrillation such as hypertension and obesity will also serve the market as drivers. The future growth of this market will be ensured by the introduction of advanced treatment procedures such as hybrid ablation and the rising prevalence of atrial fibrillation in emerging Asian economies.

On account of the fact that pharmacological treatment procedures are more frequently administered to the patients suffering from atrial fibrillation and are a cheaper alternative to non-pharmacological procedures, pharmacological procedures held the majority of market share in 2012. With the introduction of new drugs such as Bristol Myer Squibb's NTC-801, Merck's Vernakalant, Boehringer Ingelheim's Pradaxa, the market share of pharmacological treatment procedures is expected to further increase by 2019.

The non-pharmacological treatment market was led by the catheter ablation market and its market share was valued at over 45 percent in 2012. The introduction of new catheter ablation systems, such as CardioFocus's HeartLight Endoscopic Ablation System (EAS) laser ablation catheter, Endosense's TactiCath and Biosense Webster's ThermoCool SmartTouch, will help the catheter ablation market to further enhance its market share by 2019.

The radiofrequency based catheter ablation treatment for atrial fibrillation market led the catheter ablation market in terms of market share in 2012 majorly on account of the facts that it has a relatively lower procedural duration and cost and has high success rates associated with it.

High prevalence of atrial fibrillation, coupled with the availability of high disposable incomes amongst patients and sophisticated healthcare infrastructure, has led the North American atrial fibrillation market to hold the majority of the market share in 2012. However, this region is expected to lose its market share to relatively faster growing Asia-Pacific region.

Some of the key players of this market include Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Bayer/Johnson & Johnson, Medtronic, Inc., St. Jude Medical, Inc. and AtriCure, Inc.

Atrial fibrillation is a type of cardiac arrhythmia distinguished by an abnormal cardiac rhythm caused by a disturbance in heart’s electrical system. Atrial fibrillation (AF) is one of the most commonly occurring cardiac rhythm conditions. Being a potentially life threatening disease and expensive to treat, the overall healthcare system views the treatment for this condition as a strategically critical area to address. This report analyzes the market for atrial fibrillation market from the point of view of various pharmacological and non-pharmacological treatment products used for the treatment of AF.

The pharmacological AF treatment market has been further classified into the specific drugs commonly used for treating AF, namely anti-arrythmics and anti-coagulants. The non-pharmacological atrial fibrillation devices market has been further sub-divided into therapeutic procedures such as catheter ablation procedures, maze surgery and electric cardioversion. The major methods of catheter ablation procedures studied in this report include radiofrequency, high intensity focused ultrasound (HIFU), cryoablation, microwave ablation and laser catheter ablation. Each of these segments and their sub-classification is analyzed on the basis of their market size and their forecast for the period 2011 to 2019, in terms of USD million.

Related Report : Medical Fiber Optics Market
http://www.transparencymarketresearch.com/medical-fiber-optics-market.html

The compounded annual growth rate (CAGR) for all the above segments has been provided for the forecast period from 2013 to 2019, considering 2012 as the base year. In terms of geography, the market for atrial fibrillation treatment has been categorized into four geographical markets namely, North America, Europe, Asia-Pacific and Rest of the World (RoW).

The market size and forecast for all the major segments, along with their growth rate, by regions has been provided in the report. The market overview section of the report includes the qualitative analysis of the atrial fibrillation treatment market in terms of environmental factors such as drivers, restraints and opportunities, market attractiveness analysis and Porter’s five forces analysis.

Browse Blog: http://www.tmrblog.com/
Browse all Market Research reports: http://www.transparencymarketresearch.com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11294058.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Business Forecaster and Global Futurist Jack Uldrich to Keynote Indianapolis YPO Event
2. Global NAS Market 2012-2016 - New Report Available
3. Global Cardiac Bio Implant Devices (Implantable Cardiac Pacemakers, Heart Valve, Coronary Stent, Peripheral Stent, Ventricular Assist Device)
4. Global Melanoma Therapeutics Market 2012-2016
5. Global Dental Implants Market 2012-2016
6. Global Green (Sustainable) Packaging Market 2012-2016
7. Facial Injectables Industry 2013 Global Analysis in New Report at MaretReportsOnline.com
8. BCC Research Publishes A New Report On Global Markets For Telemedicine Technologies
9. Global Survey Shows Personal Mobile Computing Devices Growing Into a Major Cyber Security Concern
10. Antibiotic Resistance 2013: A Global Market Study
11. Congenital Heart Disease Global Clinical Trials Review, H2, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... 2016 , ... May 26, 2016- In search of the K. Warriors, Shaolin ... of “K Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 West ... and hosted by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This is ...
(Date:5/27/2016)... ... 27, 2016 , ... Southland Log Homes , designer and manufacturer of ... kits, which can be found on its website at SouthlandLogHomes.com. , The designs of ... they highlight the craftsmanship of timber post and beam construction. The result is ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... With over ... to walk, the demand for a sustainable product to aid in the rehabilitation process ... aid in the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Beleza Medspa ... body fat composition regulations. This is the first time that Coolsculpting is being ... at least every six months to ensure they meet the prescribed body-fat standard, measured ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team ... and food industries. Aside from its GMP accreditation, Validation Center is also a ... certified products, services and staff. , Validation Center is ISO17025 accredited and only ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharmaceutical company focused on late-stage drug development, ... Dexcel Pharma of pivotal batches required for ... Drug Administration (FDA). This follows Kitov,s announcement ... III trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 ... bedient dringenden Bedarf zur ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung ... zu sein. Ein erstes Projekt wird die Entwicklung ...
Breaking Medicine Technology: